NO 20 JAFO BUS STOP OPPOSITE BOKKU SUPERMARKET, IGBOELERIN, LAGOS
+237 6 50 05 58 64
+44 77 21 66 83 27
+234 916 457 7696
Ideas Worth Exploring
GF Journal brings together research, insights, and discussions that shape today’s industries.
Explore ideas that challenge thinking and inspire progress.
Submit your manuscripts today and become part of our community!
At GF College, students gain:
Register with us today
#gfhealthe
Good health begins before symptoms appear. At GF Healthcare, we focus on early detection, preventive screenings, and personalized guidance to keep you ahead of potential health risks. Take control of your wellness today.
Nigeria has taken a significant step in strengthening its HIV prevention strategy with the introduction of Lenacapavir, a long-acting injectable medication designed to help prevent HIV infection.
The new medication was approved by Nigeria’s Coordinating Minister of Health and Social Welfare, Muhammad Ali Pate, with support from the Global Fund. Its arrival marks an important milestone in the country’s ongoing efforts to reduce new HIV infections and improve access to innovative prevention tools.
Lenacapavir is used for pre-exposure prophylaxis (PrEP)—a medical approach that helps protect individuals who are at higher risk of contracting HIV. Unlike traditional oral PrEP medications that must be taken daily, Lenacapavir is administered as an injection only twice a year, offering a more convenient option for many people.
Public health experts believe this long-acting treatment could significantly improve adherence to HIV prevention strategies. For many individuals, maintaining a daily medication routine can be challenging, and a twice-yearly injection may help increase consistent protection.
According to Adebobola Bashorun, National Coordinator of the National HIV Viral Hepatitis and STDs Control Programme, the introduction of Lenacapavir demonstrates Nigeria’s commitment to adopting evidence-based innovations in the fight against HIV.
He noted that expanding prevention options while strengthening service delivery will help reduce new infections and improve health outcomes across the country. The programme, working alongside national and international partners, plans to ensure the safe rollout and effective integration of Lenacapavir into Nigeria’s HIV prevention services.
Through voluntary licensing agreements with generic pharmaceutical manufacturers, Lenacapavir is expected to become available in Nigeria and 119 other low- and middle-income countries at an estimated cost of about $40 per person annually.
Health officials say the introduction of this long-acting HIV prevention injection represents a major advancement in global HIV prevention efforts and brings Nigeria closer to the goal of ending HIV as a public health threat.
JOB ADVERTISEMENT
Position: Head of Research and Journal Publications
Organization: GF Health and Edu Consults Int’l Ltd
Location: Lagos, Nigeria (Hybrid / Remote collaboration possible)
About the Organization:
GF Health and Edu Consults Int’l Ltd is a healthcare, education, research, and consulting organization committed to advancing healthcare knowledge, professional training, managing and treating diseases, and evidence-based practice. The organization promotes scholarly research and academic publishing through its official journal, Global Focus Interdisciplinary Journal of Health and Sciences (GFIJHS).
Position Summary:
GF Health and Edu Consults Int’l Ltd is seeking a qualified Researcher to serve as Head of Research and Journal Publications. The successful candidate will coordinate the organization’s research initiatives and oversee the editorial management, peer-review process, and publication of the Global Focus Interdisciplinary Journal of Health and Sciences (GFIJHS).
Key Responsibilities:
-Lead and coordinate research projects within the organization.
Application Requirements:
Interested candidates should submit:
Contact Information: No. 20 JAFO Bus Stop, Igboelerin, Ojo, Lagos, Nigeria Phone: +234 707 029 4762
For more information about the organization: https://gfhealtheduintl.com
GF Health and Edu Consults Int’l Ltd is committed to excellence in healthcare education, research, and professional development.
“🚀 Showcase Your Research Globally! 🚀
Submit your papers today published by GFIJHS
📰 Why publish with us?
For book publication, consider:
“📚 Turning Ideas into Books! 📚
Partner with GF health and Edu Consult to publish your book!
AcademicPublishing #HealthcareJournal #ResearchOpportunity #PublishWithUs”
“🚀 Launching Careers in Healthcare! 🚀
Enroll now at GFHECIL College of Health Technology and turn your passion into a profession!
📚 Programs:
Apply now and start your journey at www.gfhealtheduintl.com
Nigeria is set to take a major step forward in HIV prevention as the Federal Government announces plans to introduce a groundbreaking long-acting prevention drug, Lenacapavir, in March 2026.
According to the (NACA), consignments of Lenacapavir (LEN) are expected to arrive in the country in March, marking a significant milestone in Nigeria’s efforts to curb new HIV infections and accelerate progress toward epidemic control.
Lenacapavir is a long-acting HIV prevention medication used as pre-exposure prophylaxis (PrEP). Unlike daily oral PrEP options, Lenacapavir is administered as an injection only twice a year, offering a more convenient alternative for individuals at risk of HIV infection.
Clinical trials have shown that Lenacapavir significantly reduces the risk of HIV infection, providing almost total protection when used as directed. This innovation is expected to improve adherence rates and expand access to effective prevention for populations who may struggle with daily medication.
In a statement released on March 2, NACA confirmed that the Government of Nigeria (GON) is advancing preparations for the structured introduction and rollout of Lenacapavir as PrEP.
The agency emphasized that this move is part of the government’s broader commitment to strengthening HIV prevention strategies and achieving epidemic control nationwide.
“Commodities are expected in country in March 2026,” the statement noted, signaling that preparations are already in advanced stages.
NACA revealed that Nigeria will adopt a phased introduction approach, ensuring a quality-assured and well-coordinated rollout. Landscape and readiness assessments have already been completed in 10 priority states:
These assessments evaluated service delivery capacity and identified specific implementation needs in each state.
To ensure smooth implementation, NACA has conducted a national training of trainers in Abuja, followed by step-down training sessions for healthcare workers in the selected states.
Additionally, information, education, and communication (IEC) materials have been developed to support public awareness and community engagement ahead of the rollout.
The introduction of Lenacapavir represents a transformative shift in HIV prevention in Nigeria. By offering a twice-yearly injectable option, the country is expanding access to innovative, user-friendly prevention tools that could significantly reduce new infections.
As March 2026 approaches, stakeholders across the health sector are working to ensure that the rollout is structured, inclusive, and impactful — bringing Nigeria one step closer to ending the HIV epidemic.
